Evaluation of Bone Scan Index as a Prognostic Tool in Breast Cancer Patients with Bone Metastasis

被引:0
作者
De Feo, Maria Silvia [1 ]
Frantellizzi, Viviana [1 ]
Di Rocco, Arianna [2 ]
Farcomeni, Alessio [3 ]
Matto, Antonio [1 ]
Marongiu, Andrea [4 ]
Nuvoli, Susanna [4 ]
Spanu, Angela [4 ]
De Vincentis, Giuseppe [1 ]
机构
[1] Sapienza Univ Rome, Dept Radiol Sci Oncol & Anatomopathol, Rome, Italy
[2] Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Rome, Italy
[3] Univ Roma Tor Vergata, Dept Econ & Finance, Rome, Italy
[4] Univ Sassari, Dept Med Surg & Expt Sci, Unit Nucl Med, Sassari, Italy
关键词
Bone scan index; breast cancer; bone metastasis; bone scintigraphy; overall survival ( OS); tumor load; COMPLICATIONS; RISK;
D O I
10.2174/1874471016666230509113108
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Bone metastatic involvement represents a leading cause of death in patients with advanced breast cancer (BC). At present, it is not clear whether the bone metastatic load might impact Overall Survival (OS) in patients with bone metastatic BC at diagnosis. For this purpose, we used the Bone Scan Index (BSI), which is a reproducible and quantitative expression of tumor load observed at bone scintigraphy. Objective: The aim of this study was to associate BSI with OS in bone metastatic BC patients. Methods: In this retrospective study, we enrolled BC patients with bone metastases at the scintigraphic bone scan performed for staging purposes. The BSI was calculated through the DASciS software, and statistical analysis was carried out. Other clinical variables relevant to OS analysis were taken into account. Results: Of a total of 94 patients, 32% died. In most cases, the histotype was ductal infiltrating carcinoma. The median OS from diagnosis was 72 months (CI 95%: 62-NA). The univariate analysis with COX regression showed that only hormone therapy significantly correlates with OS (HR 0.417, CI 95%: 0.174-0.997, p < 0.049). As concerning BSI, the statistical analysis showed that it does not predict OS in BC patients ( HR 0.960, 95% CI: 0.416-2.216, p < 0.924). Conclusion: Although the BSI significantly predicts OS in prostate cancer and in other tumors, we observed that the metastatic load of bone disease has not a key role in prognostic stratification in our population.
引用
收藏
页码:284 / 291
页数:8
相关论文
共 33 条
[1]   Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide [J].
Anand, Aseem ;
Morris, Michael J. ;
Larson, Steven M. ;
Minarik, David ;
Josefsson, Andreas ;
Helgstrand, John T. ;
Oturai, Peter S. ;
Edenbrandt, Lars ;
Roder, Martin Andreas ;
Bjartell, Anders .
EJNMMI RESEARCH, 2016, 6
[2]  
Bradski G, 2000, DR DOBBS J, V25, P120
[3]   Prognostic factors for skeletal complications from metastatic bone disease in breast cancer [J].
Brown, Janet E. ;
Cook, Richard J. ;
Lipton, Allan ;
Costa, Luis ;
Coleman, Robert E. .
BREAST CANCER RESEARCH AND TREATMENT, 2010, 123 (03) :767-779
[4]  
Cook Gary J. R., 2000, Cancer, V88, P2927, DOI 10.1002/1097-0142(20000615)88:12+<2927::AID-CNCR8>3.3.CO
[5]  
2-M
[6]   Role of Bone Targeting Agents in the Prevention of Bone Metastases from Breast Cancer [J].
D'Oronzo, Stella ;
Silvestris, Erica ;
Paradiso, Angelo ;
Cives, Mauro ;
Tucci, Marco .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (08)
[7]  
Even-Sapir E, 2006, J NUCL MED, V47, P287
[8]   A modified sentinel node and occult lesion localization (SNOLL) technique in non-palpable breast cancer: a pilot study [J].
Follacchio, Giulia Anna ;
Monteleone, Francesco ;
Anibaldi, Paolo ;
De Vincentis, Giuseppe ;
Iacobelli, Silvia ;
Merola, Raffaele ;
D'Orazi, Valerio ;
Monti, Massimo ;
Pasta, Vittorio .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2015, 34
[9]   223Ra Therapy of Advanced Metastatic Castration-Resistant Prostate Cancer: Quantitative Assessment of Skeletal Tumor Burden for Prognostication of Clinical Outcome and Hematologic Toxicity [J].
Fosbol, Marie Obro ;
Petersen, Peter Meidahl ;
Kjaer, Andreas ;
Mortensen, Jann .
JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (04) :596-602
[10]   Overall survival in mCPRC patients treated with Radium-223 in association with bone health agents: a national multicenter study [J].
Frantellizzi, Viviana ;
Monari, Fabio ;
Mascia, Manlio ;
Costa, Renato ;
Rubini, Giuseppe ;
Spanu, Angela ;
Farcomeni, Alessio ;
Rizzini, Elisa Lodi ;
Cindolo, Luca ;
Licari, Maria ;
Lavelli, Valentina ;
Nuvoli, Susanna ;
Ricci, Maria ;
Dionisi, Valeria ;
Nappi, Anna Giulia ;
De Vincentis, Giuseppe .
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2020, 96 (12) :1608-1613